Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pleuropulmonary blastoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms 1Hemangiosarcoma 1

Interventions

Cyclophosphamide 23Temozolomide 14Filgrastim 13Irinotecan 12Melphalan 11Etoposide 10Carboplatin 9Vincristine 8Peripheral Blood Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8X-Rays 7Topotecan 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Busulfan 7fludarabine 6Thiotepa 6Phantoms, Imaging 6fludarabine phosphate 5Radiotherapy 5Biopsy 5Antilymphocyte Serum 5Oxaliplatin 4Nuclear Medicine Department, Hospital 4Nivolumab 4Methylprednisolone 4Ifosfamide 4Cisplatin 4palbociclib 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Ado-Trastuzumab Emtansine × Sarcoma × Clear all
NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

Phase 2 Completed
62 enrolled 15 charts
CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡